Core Viewpoint - The company reported a net profit loss of approximately 724.52 million yuan for the year 2024, with no cash dividends or stock bonuses proposed for shareholders [33][87]. Company Overview - The company specializes in the research, production, and sales of patented innovative traditional Chinese medicine, while also expanding into biopharmaceuticals and the health industry [4][5]. - The company has developed a unique research model for innovative traditional Chinese medicine, focusing on major diseases and leveraging its strong scientific research capabilities [5][6]. Business Segments Traditional Chinese Medicine - The company holds 17 patented traditional Chinese medicines, covering eight major clinical disease systems, with leading positions in cardiovascular and respiratory disease treatments [5][19]. - Key products include Tongxinluo capsules, which treat coronary heart disease and cerebral infarction, and have received multiple national science and technology awards [8]. Biopharmaceuticals - The company has established a comprehensive development strategy for biopharmaceuticals, including international registration and global sales [6]. - It has received approvals for 13 ANDA products in the U.S. market and has submitted registration applications in 53 countries [6][20]. Health Industry - The company is actively developing health products based on traditional Chinese health theories, integrating modern technology [7]. - It has launched a series of health products aimed at various health needs, including heart health and anti-aging [7]. Financial Performance - The company achieved a total revenue of approximately 6.51 billion yuan in 2024, with a significant net loss [33]. - The proposed profit distribution plan for 2024 includes no cash dividends or stock bonuses, reflecting the company's current financial situation [87]. Market Position - The company ranks 7th among traditional Chinese medicine companies in China and 30th in the broader pharmaceutical industry [17]. - Despite a declining trend in the market for traditional Chinese medicine for cardiovascular diseases, the company has maintained a growing market share in oral formulations [19]. Product Performance - The market share of key products such as Tongxinluo capsules has increased from 13.64% in 2015 to 17.69% in the first half of 2024 [19]. - The company’s diabetes medication, Jinlida granules, saw its market share rise from 4.42% in 2015 to 16.20% in the first half of 2024 [20].

石家庄以岭药业股份有限公司 证券代码：002603 证券简称：以岭药业 公告编号：2025-020 关于化药创新药"G201-Na 胶囊"药物临床试验申请获 得受理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 石家庄以岭药业股份有限公司（以下简称"公司"）于 2025 年 4 月 29 日收到 国家药品监督管理局核准签发的《受理通知书》，现将相关情况公告如下： 一、临床试验申请主要内容 药物名称：G201-Na 胶囊 受 理 号：CXHL2500424，CXHL2500425 受理日期：2025 年 04 月 29 日 剂 型：胶囊剂 适 应 症：辅助生殖，用于控制性超促排卵治疗的患者，防止提前排卵。 申请事项：境内生产药品注册临床试验 申 请 人：石家庄以岭药业股份有限公司 通知书意见：自受理之日起 60 日内，未收到药审中心否定或质疑意见的， 申请人可以按照提交的方案开展临床试验。 二、G201-Na 胶囊相关情况 G201-Na胶囊项目是公司自主研发、具有独立知识产权的1类化学新药。本 品为小分子促性腺激素释放激素（GnRH）受体拮抗剂。可以阻 ...

Group 1: Product Development and Clinical Trials - The company plans to submit 1-2 new products for approval each year, with recent submissions including products for chronic cholecystitis and rheumatoid arthritis [2] - Currently, there are 6 products in clinical stages, with one in Phase III for treating children's colds and five in Phase II for various conditions [2][3] - The company has completed the registration of 536 products and has a 90% average registration rate across 14 provinces for formula granules [5] Group 2: Health Industry Progress - The company has developed a comprehensive health product system integrating traditional Chinese medicine with modern technology, focusing on health management and product development [4] - Key promoted products include health foods and functional beverages, with significant revenue growth expected in 2024 [4] Group 3: Sales Strategies and Market Expansion - The company is enhancing sales of its BaZi products through retail, e-commerce, and partnerships, aiming to build brand recognition and customer loyalty [6][7] - The company has seen rapid growth in BaZi product sales in Q1 2025, with strategies to improve customer adherence and long-term management [6][7] Group 4: International Market Development - The company aims to enhance the international influence of traditional Chinese medicine by promoting its unique theories and establishing academic collaborations globally [11][12] - It has established over 130 professional committees abroad and has received approvals for its patented traditional medicines in over 50 countries [12] Group 5: OTC Product Strategy - The company’s Lianhua Qingke product transitioned to OTC status in November 2023, which is expected to create new marketing opportunities and enhance sales through flexible promotion strategies [13]

Core Viewpoint - Yiling Pharmaceutical reported a net loss for 2024 due to revenue reduction from expiring respiratory products and increased inventory impairment, but maintains high R&D investment levels, with over 900 million yuan allocated, representing 13.94% of revenue, which is leading in the industry [1][5]. R&D Investment - Yiling Pharmaceutical has a strong R&D capability based on its unique theory of network disease, which has led to a nearly 25-fold increase in R&D investment since 2008 [2]. - The company continues to maintain high R&D investment levels, with 900 million yuan in 2024, ranking among the top in the industry [5]. Product Development and Pipeline - The company has 17 patented new drugs, with 11 included in the national medical insurance directory and 5 in the national essential drug list [5]. - Yiling Pharmaceutical has ongoing registration applications for two innovative traditional Chinese medicine products and three chemical drug products, enhancing its product pipeline [6]. Market Performance - Yiling Pharmaceutical's respiratory and cardiovascular products lead their respective markets, with Lianhua Qingwen capturing 24.36% of the cold medicine market in public healthcare [7]. - The company’s core cardiovascular products hold a combined market share of 17.69% in the public healthcare sector [7]. New Growth Areas - The company is expanding into the health and wellness sector, with products targeting blood lipid regulation, sleep improvement, and blood sugar control [8]. - Yiling Pharmaceutical's OTC product Baizi Bujin Capsule is highlighted as a potential new pillar product, supported by extensive evidence from clinical studies [8].

石家庄以岭药业股份有限公司董事会 2025 年 4 月 29 日 关于独立董事独立性自查情况的专项意见 根据《上市公司独立董事管理办法》《深圳证券交易所股票上市规则》 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》 等要求，就石家庄以岭药业股份有限公司（以下简称"公司"）第八届董事会在 任独立董事刘骁悍先生、陈刚先生、柴振国先生的独立性情况进行评估并出具 如下专项意见： 经核查独立董事刘骁悍先生、陈刚先生、柴振国先生的任职经历及其签署 的独立性自查文件，上述人员未在公司担任除独立董事以外的任何职务，也未 在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关系 或其他可能妨碍其进行独立客观判断的关系，不存在影响独立董事独立性的情 况，符合《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管 指引第 1 号——主板上市公司规范运作》及公司《独立董事制度》中对独立董 事独立性的相关要求。 石家庄以岭药业股份有限公司 董事会 ...

石家庄以岭药业股份有限公司 2024 年度独立董事述职报告 董事会专门委员会任职情况：第八届董事会提名委员会召集人、薪酬与考核 委员会委员、战略与规划委员会委员、审计委员会委员。 （二）关于独立性自查情况 根据《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指 引第 1 号—主板上市公司规范运作》等相关规定，本人作为公司独立董事，对自 身独立性情况进行了自查。2024 年度，本人未在公司担任除独立董事以外的任 何职务，也未在公司控股股东、实际控制人及其附属企业担任任何职务，与公司 以及公司控股股东、实际控制人及其附属企业之间不存在利害关系或其他可能妨 碍本人进行独立客观判断的关系，本人任职符合《上市公司独立董事管理办法》 等规定的独立性要求，不存在影响独立性的情形。 二、2024 年度履职情况 （刘骁悍） 本人作为石家庄以岭药业股份有限公司（以下简称"公司"）的独立董事，严 格按照《公司法》《上市公司治理准则》《上市公司自律监管指引第 1 号——主板 上市公司规范运作》等法律法规以及《公司章程》、《公司独立董事制度》的规定， 本着客观、公正、独立的原则，勤勉尽责，积极发挥独立董事作用，维护公司整 ...

石家庄以岭药业股份有限公司 2024 年度独立董事述职报告 （柴振国） （二）关于独立性自查情况 根据《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指 引第 1 号—主板上市公司规范运作》等相关规定，本人作为公司独立董事，对自 身独立性情况进行了自查。2024 年度，本人未在公司担任除独立董事以外的任 何职务，也未在公司控股股东、实际控制人及其附属企业担任任何职务，与公司 以及公司控股股东、实际控制人及其附属企业之间不存在利害关系或其他可能妨 碍本人进行独立客观判断的关系，本人任职符合《上市公司独立董事管理办法》 等规定的独立性要求，不存在影响独立性的情形。 二、2024 年度履职情况 本人自 2024 年 6 月任职后，积极参加公司召开的董事会，认真审阅会议相 关材料，积极参与各项议案的讨论并提出合理建议，为董事会的正确、科学决策 发挥积极作用。2024 年度，公司董事会的召集召开符合法定程序，重大经营决 策事项和其他重大事项均履行了相关的审批程序。 （一）本人出席会议情况 本人作为石家庄以岭药业股份有限公司（以下简称"公司"）的独立董事，严 格按照《公司法》《上市公司治理准则》《上市公司自律 ...

石家庄以岭药业股份有限公司 董事会专门委员会任职情况：第八届董事会审计委员会召集人。 （二）关于独立性自查情况 2024 年度独立董事述职报告 （陈刚） 本人作为石家庄以岭药业股份有限公司（以下简称"公司"或"以岭药业"） 的独立董事，严格按照《公司法》《上市公司治理准则》《上市公司自律监管指引 第 1 号——主板上市公司规范运作》等法律法规以及《公司章程》、公司《独立 董事制度》的规定，本着客观、公正、独立的原则，勤勉尽责，积极发挥独立董 事作用，维护公司整体利益和全体股东尤其是中小股东的合法权益。 现将本人 2024 年度履行独立董事职责情况总结如下： 一、基本情况 （一） 独立董事基本情况 陈刚，男，1964 年出生，中国国籍，无境外永久居留权，管理学硕士，现 为中央财经大学会计学院教授，曾任北京中惠会计师事务所常务副所长、北京 国家税务局稽查局会计顾问、兰州经济技术开发区副主任、新华网、舍得酒 业、佳讯飞鸿、北京科锐、引力传媒等多家上市公司独立董事。现任北京佳讯 飞鸿电气股份有限公司、爱美客技术发展股份有限公司独立董事。2023 年 2 月 起任公司独立董事。 根据《上市公司独立董事管理办法》《深圳证 ...

石家庄以岭药业股份有限公司 关于营业收入扣除事项专项审核报告 勤信专字【2025】第 1102 号 | 关于营业收入扣除事项专项审核报告 | | 1-2 | | --- | --- | --- | | 内 容 营业收入扣除情况明细表 | 页 3 | 次 | 目 录 中勤万信会计师事务所 地址：北京西直门外大街 112 号阳光大厦 10 层 电话：（86-10）68360123 传真：（86-10）68360123-3000 邮编：100044 石家庄以岭药业股份有限公司 关于营业收入扣除事项专项审核报告 勤信专字【2025】第 1102 号 石家庄以岭药业股份有限公司全体股东： 我们接受委托，对石家庄以岭药业股份有限公司（以下简称"以岭药业"）2024 年度财务报表进行审计，并出具了勤信审字【2025】第 0752 号审计报告。在此 基础上我们检查了贵公司编制的后附 2024 年度营业收入扣除情况明细表（以下 简称"明细表"）。该明细表已由以岭药业管理层按照深圳证券交易所（以下简称 "监管机构"）发布的《深圳证券交易所股票上市规则（2024 年修订）》及《深 圳证券交易所上市公司自律监管指南第 1 号——业务 ...